{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:32:57Z","timestamp":1791567177997,"version":"4.3.4"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nitric Oxide"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.niox.2018.05.001","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T11:59:22Z","timestamp":1525521562000},"page":"88-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases"],"prefix":"10.1016","volume":"77","author":[{"given":"Peter","family":"Sandner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Becker-Pelster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Peter","family":"Stasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.niox.2018.05.001_bib1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1073\/pnas.0304264101","article-title":"Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment","volume":"101","author":"Ahluwalia","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"18","key":"10.1016\/j.niox.2018.05.001_bib2","doi-asserted-by":"crossref","first-page":"29613","DOI":"10.18632\/oncotarget.16769","article-title":"Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension","volume":"8","author":"Amirjanians","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.niox.2018.05.001_bib3","series-title":"BAY41\u20132272 Attenuates Pulmonary Arteries Hypertrophy in a Rodent Model of Chronic Thromboembolic Pulmonary Hypertension H\u00e4mostaseologie 1a","author":"Arias Loza","year":"2016"},{"key":"10.1016\/j.niox.2018.05.001_bib4","doi-asserted-by":"crossref","first-page":"H1153","DOI":"10.1152\/ajpheart.01101.2009","article-title":"Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41\u20138543, are modulated by nitric oxide","volume":"299","author":"Badejo","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.niox.2018.05.001_bib5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003495-200969090-00002","article-title":"Pulmonary hypertension in patients with chronic obstructive pulmonary disease. Advances in pathophysiology and management","volume":"69","author":"Barber\u00e0","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.niox.2018.05.001_bib6","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":"Updated evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"54","author":"Barst","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.niox.2018.05.001_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073502","article-title":"Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension","volume":"8","author":"Becker","year":"2013","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"10.1016\/j.niox.2018.05.001_bib8","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.rmed.2016.11.010","article-title":"sGC stimulators: evidence for riociguat beyond groups 1 and 4 pulmonary hypertension","volume":"122","author":"Benza","year":"2017","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.niox.2018.05.001_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/ars.2015.6591","article-title":"Thiol-based redox modulation of soluble guanylyl cyclase, the nitric oxide receptor","volume":"26","author":"Beuve","year":"2017","journal-title":"Antioxidants Redox Signal."},{"issue":"6","key":"10.1016\/j.niox.2018.05.001_bib10","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2011-200862","article-title":"Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis","volume":"71","author":"Beyer","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.niox.2018.05.001_bib11","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","article-title":"Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF\u03b2 signaling","volume":"74","author":"Beyer","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.niox.2018.05.001_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1164\/rccm.200907-0988OC","article-title":"Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension","volume":"181","author":"Blanco","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.niox.2018.05.001_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cardiores.2007.04.014","article-title":"Inhaled NO as a therapeutic agent","volume":"75","author":"Bloch","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.niox.2018.05.001_bib14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2007.11.030","article-title":"Dose-dependent beneficial hemodynamic effects of BAY 41\u20132272 in a canine model of acute pulmonary thromboembolism","volume":"581","author":"Cau","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.niox.2018.05.001_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191239","article-title":"Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation\/perfusion matching","volume":"13","author":"Chamorro","year":"2018","journal-title":"PLoS One"},{"issue":"32","key":"10.1016\/j.niox.2018.05.001_bib16","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1183\/09031936.00015608","article-title":"Pulmonary hypertension in COPD","volume":"2008","author":"Chaouat","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.niox.2018.05.001_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.niox.2018.05.001_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1464-410X.2010.09776.x","article-title":"Long-term oral treatment with BAY 41\u20132272 ameliorates impaired corpus cavernosum relaxations in a nitric oxide-deficient rat model","volume":"108","author":"Claudino","year":"2011","journal-title":"BJU Int."},{"issue":"8","key":"10.1016\/j.niox.2018.05.001_bib19","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/annrheumdis-2014-206809","article-title":"Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies","volume":"74","author":"Dees","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.niox.2018.05.001_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000092518","article-title":"BAY 41\u20132272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats","volume":"90","author":"Deruelle","year":"2006","journal-title":"Biol. Neonate"},{"key":"10.1016\/j.niox.2018.05.001_bib21","doi-asserted-by":"crossref","first-page":"L798","DOI":"10.1152\/ajplung.00119.2005","article-title":"Pulmonary vascular effects of nitricoxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep","volume":"289","author":"Deruelle","year":"2005","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.niox.2018.05.001_bib22","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.105.581405","article-title":"Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling","volume":"113","author":"Dumitrascu","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.niox.2018.05.001_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2007.06.036","article-title":"Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase","volume":"572","author":"Dunkern","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.niox.2018.05.001_bib24","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1161\/CIRCULATIONAHA.105.591321","article-title":"Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia","volume":"113","author":"Eddahibi","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.niox.2018.05.001_bib25","article-title":"Inhalative application of soluble guanylyl cyclase stimulator BAY 41\u20138543 for treatment of pulmonary arterial hypertension [abstract]","volume":"181","author":"Egemnazarov","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7480","key":"10.1016\/j.niox.2018.05.001_bib26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nature12722","article-title":"Dysfunctional nitric oxide signalling increases risk of myocardial infarction","volume":"504","author":"Erdmann","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.niox.2018.05.001_bib27","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/01.CIR.0000144469.01521.8A","article-title":"Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs","volume":"110","author":"Evgenov","year":"2004","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.niox.2018.05.001_bib28","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.niox.2018.05.001_bib29","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1164\/rccm.200707-1121OC","article-title":"Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation","volume":"176","author":"Evgenov","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.niox.2018.05.001_bib30","first-page":"183","article-title":"Stimulation of soluble guanylate cyclase attenuates bleomycin- induced pulmonary fibrosis","author":"Evgenov","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.niox.2018.05.001_bib31","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.niox.2018.05.001_bib32","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure","volume":"60","author":"Follmann","year":"2017","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.niox.2018.05.001_bib33","doi-asserted-by":"crossref","first-page":"L755","DOI":"10.1152\/ajplung.00138.2010","article-title":"Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension","volume":"301","author":"Chester","year":"2011","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"6","key":"10.1016\/j.niox.2018.05.001_bib34","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/bph.14137","article-title":"The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis","volume":"175","author":"Flores-Costa","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.niox.2018.05.001_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1440-1681.2007.04524.x","article-title":"Effect of BAY 41\u20132272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs","volume":"34","author":"Freitas","year":"2007","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"12","key":"10.1016\/j.niox.2018.05.001_bib36","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00210-015-1176-4","article-title":"From bedside to bench\u2013meeting report of the 7th International Conference on cGMP \u201ccGMP: generators, effectors and therapeutic implications\u201d in Trier, Germany, from June 19th to 21st 2015","volume":"388","author":"Friebe","year":"2015","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"4","key":"10.1016\/j.niox.2018.05.001_bib37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.niox.2018.05.001_bib38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.niox.2018.05.001_bib39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.niox.2018.05.001_bib40","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.niox.2018.05.001_bib41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/14728210903551271","article-title":"Emerging drugs for pulmonary hypertension","volume":"15","author":"Girgis","year":"2010","journal-title":"Expet Opin. Emerg. Drugs"},{"issue":"6","key":"10.1016\/j.niox.2018.05.001_bib42","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1165\/rcmb.2014-0092OC","article-title":"Guanylyl cyclase activation reverses resistive breathing-induced lung injury and inflammation","volume":"52","author":"Glynos","year":"2015","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.niox.2018.05.001_bib43","first-page":"761","article-title":"The sGC stimulator BAY 41\u20138543 totally reverses hypoxia induced pulmonary hypertension [abstract]","volume":"31","author":"Hedelin","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.niox.2018.05.001_bib44","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.jacc.2009.04.008","article-title":"Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension","volume":"54","author":"Hoeper","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.niox.2018.05.001_bib45","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1183\/09031936.00213911","article-title":"Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial","volume":"41","author":"Hoeper","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.niox.2018.05.001_bib46","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1182\/blood.V84.12.4226.bloodjournal84124226","article-title":"YC-1, a novel activator of platelet guanylate cyclase","volume":"84","author":"Ko","year":"1994","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.niox.2018.05.001_bib47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5301\/jsrd.5000207","article-title":"Emerging strategies for treatment of systemic sclerosis","volume":"1","author":"Khanna","year":"2016","journal-title":"Journal of Scleroderma and Related Disorders"},{"issue":"4","key":"10.1016\/j.niox.2018.05.001_bib48","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3892\/etm.2017.4149","article-title":"Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock","volume":"13","author":"Kronas","year":"2017","journal-title":"Exp Ther Med."},{"issue":"8","key":"10.1016\/j.niox.2018.05.001_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043433","article-title":"The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats","volume":"7","author":"Lang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.niox.2018.05.001_bib50","doi-asserted-by":"crossref","first-page":"H1141","DOI":"10.1152\/ajpheart.00767.2010","article-title":"Dependence of Golgi apparatus integrity on nitric oxide in vascular cells: implications in pulmonary arterial hypertension","volume":"300","author":"Lee","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.niox.2018.05.001_bib51","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1378\/chest.129.3.746","article-title":"Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis","volume":"129","author":"Lettieri","year":"2006","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.niox.2018.05.001_bib52","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1748-1716.2012.02445.x","article-title":"sGC stimulation totally reverses hypoxia-induced pulmonary vasoconstriction alone and combined with dual endothelin-receptor blockade in a porcine model","volume":"206","author":"Lundgren","year":"2012","journal-title":"Acta Physiol."},{"issue":"3","key":"10.1016\/j.niox.2018.05.001_bib53","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/annrheumdis-2017-212489","article-title":"Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators","volume":"77","author":"Matej","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.niox.2018.05.001_bib54","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension: a report of the american college of cardiology foundation task force on expert consensus documents and the american heart association","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.niox.2018.05.001_bib55","article-title":"sGC-stimulation vs. PDE5-inhibition in a model of chronic thromboembolic pulmonary hypertension (CTEPH)","volume":"185","author":"Mercier","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.niox.2018.05.001_bib56","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jacc.2009.04.018","article-title":"Cellular and molecular basis of pulmonary arterial hypertension","volume":"54","author":"Morrell","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.niox.2018.05.001_bib57","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0140-6736(02)46032-1","article-title":"Nitro-glycerine as a remedy for angina pectoris","volume":"1","author":"Murrell","year":"1879","journal-title":"Lancet"},{"issue":"Suppl1","key":"10.1016\/j.niox.2018.05.001_bib58","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.rmed.2016.11.003","article-title":"Idiopathic interstitial pneumonia-associated pulmonary hypertension: a target for therapy?","volume":"122","author":"Nathan","year":"2017","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.niox.2018.05.001_bib59","doi-asserted-by":"crossref","first-page":"H792","DOI":"10.1152\/ajpheart.00953.2010","article-title":"Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60\u20132770, are not dependent on endogenous nitric oxide or reduced heme","volume":"300","author":"Pankey","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"5","key":"10.1016\/j.niox.2018.05.001_bib60","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1165\/rcmb.2017-0292OC","article-title":"NO-independent sGC activation improves vascular function and cardiac remodeling in sickle cell disease","volume":"58","author":"Potoka","year":"2018","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.niox.2018.05.001_bib61","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1152\/physrev.00029.2006","article-title":"Nitric oxide and peroxynitrite in health and disease","volume":"87","author":"Pacher","year":"2007","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.niox.2018.05.001_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.niox.2012.02.004","article-title":"Effect of chronic sodium nitrite therapy on monocrotaline-induced pulmonary hypertension","volume":"27","author":"Pankey","year":"2012","journal-title":"Nitric Oxide"},{"issue":"216","key":"10.1016\/j.niox.2018.05.001_bib63","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2016.04.098","article-title":"Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice","volume":"1","author":"Pradhan","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.niox.2018.05.001_bib64","series-title":"European Medicine Agency","author":"Press Release","year":"2016"},{"key":"10.1016\/j.niox.2018.05.001_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3293584","article-title":"Effect of riociguat and sildenafil on right heart remodeling and function in pressure overload induced model of pulmonary arterial banding","volume":"2018","author":"Rai","year":"2018","journal-title":"BioMed Res. Int."},{"issue":"10","key":"10.1016\/j.niox.2018.05.001_bib66","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00383-014-3561-3","article-title":"The soluble guanylyl cyclase activator BAY 60-2770 potently relaxes the pulmonary artery on congenital diaphragmatic hernia rabbit model","volume":"30","author":"Rojas-Moscoso","year":"2014","journal-title":"Pediatr. Surg. Int."},{"issue":"5","key":"10.1016\/j.niox.2018.05.001_bib67","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1183\/09031936.00090614","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)","volume":"45","author":"Rubin","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.niox.2018.05.001_bib68","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000450946","article-title":"The potential of sGC modulators for the treatment of age-related fibrosis: a mini-review","volume":"63","author":"Sandner","year":"2017","journal-title":"Gerontology"},{"issue":"Suppl 1","key":"10.1016\/j.niox.2018.05.001_bib69","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence","volume":"122","author":"Sandner","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.niox.2018.05.001_bib70","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1183\/09031936.00114407","article-title":"Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension","volume":"32","author":"Schermuly","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.niox.2018.05.001_bib71","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1183\/09031936.00087114","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)","volume":"45","author":"Simonneau","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.niox.2018.05.001_bib72","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1183\/09031936.98.12020265","article-title":"Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension","volume":"12","author":"Sitbon","year":"1998","journal-title":"Eur. Respir. J."},{"issue":"20","key":"10.1016\/j.niox.2018.05.001_bib73","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.niox.2018.05.001_bib74","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-3-662-45805-1_12","article-title":"Soluble guanylate cyclase stimulators in pulmonary hypertension","volume":"218","author":"Stasch","year":"2013","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.niox.2018.05.001_bib75","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coph.2014.12.014","volume":"21","author":"Stasch","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.niox.2018.05.001_bib76","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1183\/09031936.00011308","article-title":"A randomised, controlled trial of bosentan in severe COPD","volume":"32","author":"Stolz","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.niox.2018.05.001_bib77","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2010.08.032","article-title":"BAY 41\u20132272 inhibits the development of chronic hypoxic pulmonary hypertension in rats","volume":"647","author":"Thorsen","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.niox.2018.05.001_bib78","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.117.247429","article-title":"Pharmacological characterization of IW-1973, a novel solbuble guanylate cyclase stimulator with extensive tissue distribution, anti-hypertensive, anit-inflammatory, and anit-fibrotic effects in preclinical modeks of disease","author":"Tobin","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"12","key":"10.1016\/j.niox.2018.05.001_bib79","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1097\/CCM.0b013e318226678e","article-title":"Pulmonary vascular reserve during experimental pulmonary embolism: effects of a soluble guanylate cyclase stimulator, BAY 41-8543","volume":"39","author":"Watts","year":"2011","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.niox.2018.05.001_bib80","doi-asserted-by":"crossref","first-page":"P61","DOI":"10.1186\/1471-2210-5-S1-P61","article-title":"Inhaled NO and the guanylate cyclase stimulator BAY 41\u20132272 in oleic acid induced acute lung injury in rabbits [abstract]","volume":"5","author":"Weidenbach","year":"2005","journal-title":"BMC Pharmacol."},{"issue":"11","key":"10.1016\/j.niox.2018.05.001_bib81","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1164\/rccm.201311-2037OC","article-title":"Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema","volume":"189","author":"Weissmann","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.niox.2018.05.001_bib82","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","article-title":"Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells","volume":"172","author":"Wharton","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.niox.2018.05.001_bib83","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yexcr.2015.08.014","article-title":"Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells","volume":"338","author":"Zenzmaier","year":"2015","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.niox.2018.05.001_bib84","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.yexcr.2015.02.006","article-title":"The sGC activator inhibits the proliferation and migration, promotes the apoptosis of human pulmonary arterial smooth muscle cells via the up regulation of plasminogen activator inhibitor-2","volume":"332","author":"Zhang","year":"2015","journal-title":"Exp. Cell Res."}],"container-title":["Nitric Oxide"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108986031830082X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108986031830082X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T11:15:16Z","timestamp":1571310916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108986031830082X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":84,"alternative-id":["S108986031830082X"],"URL":"https:\/\/doi.org\/10.1016\/j.niox.2018.05.001","relation":{},"ISSN":["1089-8603"],"issn-type":[{"value":"1089-8603","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases","name":"articletitle","label":"Article Title"},{"value":"Nitric Oxide","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.niox.2018.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}